Bayer Exploring Sale of Diabetes Unit for Up to $2.5B

The transcript discusses Bayer's potential sale of its diabetes device business, with private equity firms like Cinven and Triton Advisors showing interest. The unit could be valued between €1 billion and 2 billion. Bayer is also planning to list its plastics unit on the stock market and is in the process of acquiring MERCS' over-the-counter drug business for $14 billion. Additionally, Bayer might be interested in acquiring Zoetis, an animal health company previously part of Pfizer.

Which financial institution is involved in the potential sale of the diabetes device business?

• Morgan Stanley

• Goldman Sachs

• Deutsche Bank

• Credit Suisse

What is the estimated value range for the diabetes device unit sale?

• €2 billion to €3 billion

• €1 billion to €2 billion

• €500 million to €1 billion

• €3 billion to €4 billion

What is Bayer planning to list on the stock market?

• Its plastics unit

• Its consumer health unit

• Its agricultural unit

• Its pharmaceuticals unit

Which company is Bayer in the process of acquiring for $14 billion?

• Zoetis

• Pfizer

• MERCS

• Cinven

Zoetis, a company Bayer might be interested in, was separated from which major pharmaceutical company?

• Sanofi

• GlaxoSmithKline

• Pfizer

• Novartis